FDA reviews diabetic and HIV medications

Mar 27, 2008

The U.S. Food and Drug Administration has announced safety reviews of the FDA-approved medications Regranex Gel, Ziagen and Videx.

The FDA said study data suggests there might be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel to treat leg and foot ulcers.

The FDA said it was also studying data that indicate a higher risk of heart attack in patients infected with the human immunodeficiency virus who take Ziagen (abacavir) or Videx (didanosine) as part of their drug therapy.

Until all three reviews are completed, the FDA said health care professionals should evaluate the potential risks and benefits of each drug with their patients.

Copyright 2008 by United Press International

Explore further: FDA approves second vaccine against meningitis strain

add to favorites email to friend print save as pdf

Related Stories

Keeping hackers out of hospitals

Jan 07, 2015

The humble infusion pump: It stands sentinel in the hospital room, injecting patients with measured doses of drugs and writing information to their electronic medical records.

Calcium makes for an environmentally friendly pickle

Jul 08, 2014

George Washington had a collection of 476 kinds of pickles. To prevent scurvy, Christopher Columbus stocked pickles on the Niña, Pinta, and Santa Maria. Julius Caesar, believing pickles to be invigorating, ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.